EACR25-2345
Endometrial cancer (EC) remains a clinical challenge, where cancer stem cells (CSC) have been associated with chemoresistance and recurrence. In particular, a relevant expression of aldehyde dehydrogenase (ALDH) on EC has been involved in disease progression and is associated with stemness pathways, proposing its double potential as a biomarker and a molecular target. To investigate more effective and minimally invasive treatments for EC, our research focuses on a novel approach using CSC-targeted photodynamic therapy (PDT) based on modified 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-fused chlorins (PX).
A refined sphere-forming protocol was performed to obtain endometrial CSC from ECC-1, RL95-2 and HEC-1-A cell lines. To evaluate the effectiveness of a CSC-targeted PDT strategy in EC, the colocalisation of a novel class of tetrahydropyrazolo[1,5-a]pyridine-fused chlorins functionalised with aldehyde moieties (A-PX) with ALDH was verified using confocal microscopy. Then, endometrial CSC were incubated with a range of A-PX concentrations (2.5 – 10 µM) for 2 hours, followed by a light irradiation (7.5mW/cm2, 10J). To assess the expression of CSC markers, the effect of CSC-targeted PDT on CD44 and CD24 was examined through flow cytometry. Viability and cell death were determined through luminescence and confocal microscopy.
After evidence that ALDH interacts with A-PX in vitro and converts aldehydes into carboxylic acids and A-PX can internalise and accumulate in endometrial CSC, preliminary confocal studies pointed out that A-PX localise in CSC ALDH-enriched zones, facilitating the expected action mediated by ALDH. Moreover, initial findings revealed a high percentage of CD44+/CD24- cells, confirming CSC-like characteristics. CSC-targeted PDT seems not to modulate the stemness features of the ECC-1 CSC-enriched populations. Nevertheless, A-PX-based PDT notably contributed to eliminating endometrial CSC, resulting in a significant reduction in viability and the induction of cell death.
In conclusion, these results emphasise the potential of the A-PX-mediated strategy to target ALDH in vitro and within CSC, as well as the effectiveness of A-PX-based PDT for eradicating EC cells. This research represents the first steps towards developing a conservative and minimally invasive therapeutic option for challenging cases of EC. FCT supports CIBB (10.54499/UIDB/04539/2020; 10.54499/UIDP/04539/2020; 10.54499/LA/P/0058/2020); CQC (10.54499/UIDB/00313/2020; 10.54499/UIDP/00313/2020; TEMA (10.54499/UIDB/00481/2020), UIDP/00481/2020 (10.54499/UIDP/00481/2020); Projects CarboNCT (10.54499/2022.03596.PTDC) and Chem4LungCare (10.54499/PTDC/QUI-QOR/0103/2021); PhD Scholarship from FCT and European Social Fund to BS (10.54499/2020.07672.BD), BC (10.54499/2022.12013.BD) and RT (SFRH/BD/116794/2016).